ICAD Inc
NASDAQ:ICAD

Watchlist Manager
ICAD Inc Logo
ICAD Inc
NASDAQ:ICAD
Watchlist
Price: 1.72 USD 2.08%
Market Cap: 45.6m USD
Have any thoughts about
ICAD Inc?
Write Note

ICAD Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ICAD Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
ICAD Inc
NASDAQ:ICAD
Cash Equivalents
$18.8m
CAGR 3-Years
-19%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Veeva Systems Inc
NYSE:VEEV
Cash Equivalents
$1B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
23%
Inspire Medical Systems Inc
NYSE:INSP
Cash Equivalents
$147.5m
CAGR 3-Years
-11%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Cash Equivalents
$96.8m
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Cash Equivalents
$570.6m
CAGR 3-Years
6%
CAGR 5-Years
33%
CAGR 10-Years
19%
W
Waystar Holding Corp
NASDAQ:WAY
Cash Equivalents
$35.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ICAD Inc
Glance View

Market Cap
45.3m USD
Industry
Health Care

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

ICAD Intrinsic Value
1.67 USD
Overvaluation 3%
Intrinsic Value
Price

See Also

What is ICAD Inc's Cash Equivalents?
Cash Equivalents
18.8m USD

Based on the financial report for Sep 30, 2024, ICAD Inc's Cash Equivalents amounts to 18.8m USD.

What is ICAD Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-6%

Over the last year, the Cash Equivalents growth was -1%. The average annual Cash Equivalents growth rates for ICAD Inc have been -19% over the past three years , 2% over the past five years , and -6% over the past ten years .

Back to Top